Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Feb 20, 2014 (13 years ago)

Nicorette (nicotine polacrilex)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Nicorette (nicotine polacrilex) Lozenges Mini, 4 mg, Original Flavor, 20 Lozenge and 81 Lozenge Vials, OTC. Distributed by GlaxoSmithKline Consumer Healthcare, LP, Moon Township, PA 15108, Made in Switzerland. 20 Count NDC: 0135-0509-04, 81 Count NDC: 0135-0509-02.

Affected NDCs 0135-0509-02 0135-0509-04

Compare with the code on your package — it is the most precise check available.

Drug: Nicotine

Recalling firm
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1246-2014 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nicotine recalls

See all
Class III · Low risk

Nicotine Transdermal System Patch

Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability testing of individual units.

Ongoing Impurity / degradation AVEVA Drug Delivery Systems, Inc. NDC 0536-5895-88 D-0550-2026
Class III · Low risk

Nicotine Gum

Labeling: Incorrect or Missing Package Insert: The package insert included in the finished product is for the Canadian market and is not part of the current approved drug labeling.

Terminated Labeling / mix-up P & L Developments, LLC NDC 11822-3328-3 D-0004-2021
Class III · Low risk

Nicotine Polacrilex Lozenge

Failed Dissolution Specifications and Failed Tablet Specifications: High 30 minute dissolution test and presence of broken lozenges.

Terminated Dissolution failure Perrigo Holland Inc D-1558-2014

Other recalls by GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline

All 2014 recalls
Class III · Low risk

Nicorette Lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1244-2014
Class III · Low risk

Nicotine polacrilex lozenge

Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Terminated Wrong potency / content GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline D-1243-2014